ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Takeda taps Shire's global network to sell prized dengue vaccine

Japanese drugmaker to utilize sales channels from massive acquisition

Takeda Pharmaceutical is developing the first vaccine for dengue fever that can be administered to children as young as four. (Photo courtesy of the company)

TOKYO -- Takeda Pharmaceutical plans to become the first Japanese drugmaker to market vaccines on a global scale, taking advantage of access to new sales channels gained from its acquisition of Irish peer Shire last year.

Takeda is developing what would be the world's first vaccine for dengue fever that can be given to children as young as four. Dengue is a viral disease spread by mosquitoes that is endemic in much of the world, with 400 million infections and 20,000 deaths each year.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more